Rothschild & Co Upgrades Abbott Laboratories to Buy, Raises Price Target to $127
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice TargetHot
Rothschild & Co analyst Ed Ridley-Day upgrades Abbott Laboratories (NYSE:ABT) from Neutral to Buy and raises the price target from $119 to $127.
Rothschild & Co analyst Ed Ridley-Day upgrades Abbott Laboratories (NYSE:ABT) from Neutral to Buy and raises the price target from $119 to $127.